Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Abatacept, rituximab or tocilizumab
(Actemra (TN))		3件: Abatacept,
Rituximab,
Tocilizumab (Actemra ACTPen)		3件: Tocilizumab (Actemra (TN)),
Rituximab ,
Abatacept 💬 		4件: CD80,
CD86,
IL6R,
MS4A1 💬 		25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
2Actemra1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 107 💬
3Actemra(EU-licensed)1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
4Actemra, MRA1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 107 💬
5Adalimuab, Etanercept, Tocilizumab, or Abatacept
(Actemra (TN))		3件: Abatacept,
Etanercept,
Tocilizumab (Actemra ACTPen)		3件: Etanercept ,
Tocilizumab (Actemra (TN)),
Abatacept 💬 		5件: CD80,
CD86,
IL6R,
LTA,
TNF 💬 		80件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
6Corticoids+ tocilizumab 8mg/Kg/4 weeks
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
7CT-P47 AI (tocilizumab)
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
8CT-P47 PFS (tocilizumab)
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
9Decrease Tocilizumab, Abatacept
(Actemra (TN))		2件: Abatacept,
Tocilizumab (Actemra ACTPen)		2件: Tocilizumab (Actemra (TN)),
Abatacept 💬 		3件: CD80,
CD86,
IL6R 💬 		25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
10Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab
(Actemra (TN))		4件: Abatacept,
Rituximab,
Sarilumab,
Tocilizumab (Actemra ACTPen)		4件: Tocilizumab (Actemra (TN)),
Rituximab ,
Abatacept ,
Sarilumab 💬 		4件: CD80,
CD86,
IL6R,
MS4A1 💬 		25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
11INN-Tocilizumab
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 266 💬
12Intra-articular Tocilizumab
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
13MRA (Actemra)1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 107 💬
14MRA (tocilizumab)
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 107 💬
15MRA(Tocilizumab)
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 107 💬
16MRA, Actemra1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 107 💬
17Ro Actemra1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
18Ro-Actemra1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 107 💬
19RoActemra/Actemra (tocilizumab)1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 107 💬
20Subcutaneous tocilizumab
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
21Subcutaneous tocilizumab 162mg/biweekly
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
22TOCILIZUMAB
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬21件: 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
23Tocilizumab (Actemra or RoActemra)1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
24Tocilizumab (Actemra)1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
25Tocilizumab (Actemra®)1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
26Tocilizumab (MRA-SC)
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 40 💬
27Tocilizumab (TCZ)
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 56 💬
28Tocilizumab + Glucocorticoids (GCs)
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
29Tocilizumab + methotrexate(MTX)
(Actemra (TN))		2件: Methotrexate,
Tocilizumab (Actemra ACTPen)		2件: Methotrexate ,
Tocilizumab (Actemra (TN)) 💬 		3件: DHFR,
DHFR2,
IL6R 💬 		17件: Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
30Tocilizumab 162 mg
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
31Tocilizumab 162Mg/0.9Ml Autoinjector
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
32Tocilizumab 162mg/0.9ml jeringa SC
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
33Tocilizumab 162mg/0.9ml SC PFS SC
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
34Tocilizumab 162mg/0.9ml syringe SC
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
35Tocilizumab [RoActemra/Actemra]1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬4件: 46, 51, 107, 331 💬
36Tocilizumab [RoActemra]
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
37Tocilizumab and IV steroids combination
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
38Tocilizumab Infusion RoAcemtra (EU)
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 266 💬
39Tocilizumab Injectable Product
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 11 💬
40Tocilizumab Injection
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
41Tocilizumab Injection 8mg/kg
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
42Tocilizumab IV
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
43Tocilizumab plus methotrexate
(Actemra (TN))		2件: Methotrexate,
Tocilizumab (Actemra ACTPen)		2件: Methotrexate ,
Tocilizumab (Actemra (TN)) 💬 		3件: DHFR,
DHFR2,
IL6R 💬 		17件: Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
44Tocilizumab Prefilled Syringe
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 41, 46 💬
45Tocilizumab Roche
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 107 💬
46TOCILIZUMAB SC
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬3件: 41, 46, 107 💬
47Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI)
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
48Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS)
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
49Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS)
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 51 💬
50Tocilizumab treatment
(Actemra (TN))		1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
51Tocilizumab+Methotrexate(MTX)
(Actemra (TN))		2件: Methotrexate,
Tocilizumab (Actemra ACTPen)		2件: Methotrexate ,
Tocilizumab (Actemra (TN)) 💬 		3件: DHFR,
DHFR2,
IL6R 💬 		17件: Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
52Tocilizumab, Abatacept
(Actemra (TN))		2件: Abatacept,
Tocilizumab (Actemra ACTPen)		2件: Tocilizumab (Actemra (TN)),
Abatacept 💬 		3件: CD80,
CD86,
IL6R 💬 		25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬